InvestorsHub Logo
Followers 78
Posts 11422
Boards Moderated 0
Alias Born 04/03/2014

Re: None

Saturday, 08/04/2018 10:24:16 PM

Saturday, August 04, 2018 10:24:16 PM

Post# of 112
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2018 Results - Earnings Call Transcript $GLMD

https://seekingalpha.com/article/4194869

The final cost of the trial will be around $75 million
200 centers
Start by Q2-2019
Duration 52 weeks
No of patients - around 300

Study enrollment may take 12-18 months + 12 months + 3-4 months for topline results - we are looking at 32-36 months or 3 years - which is Q2-2022

If there is no buyout or partnership - we will see just dilution and SP going down
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GLMD News